Blood Clotting Accelerant (BCA) Market Report – Research, Industry Analysis Reports and Market Demands

Global Blood Clotting Accelerant (BCA) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
- 1.3.1 Overview: Global Blood Clotting Accelerant (BCA) Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Liquid
- 1.3.3 Powder
1.4 Market Analysis by Tube Type
- 1.4.1 Overview: Global Blood Clotting Accelerant (BCA) Consumption Value by Tube Type: 2021 Versus 2025 Versus 2032
- 1.4.2 Clot Activator Tube
- 1.4.3 Gel & Clot Activator Tube
1.5 Market Analysis by Application
- 1.5.1 Overview: Global Blood Clotting Accelerant (BCA) Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.5.2 Biochemical Testing
- 1.5.3 Immunological Testing
- 1.5.4 Emergency Testing
- 1.5.5 Others
1.6 Global Blood Clotting Accelerant (BCA) Market Size & Forecast
- 1.6.1 Global Blood Clotting Accelerant (BCA) Consumption Value (2021 & 2025 & 2032)
- 1.6.2 Global Blood Clotting Accelerant (BCA) Sales Quantity (2021-2032)
- 1.6.3 Global Blood Clotting Accelerant (BCA) Average Price (2021-2032)

2 Manufacturers Profiles

3 Competitive Environment: Blood Clotting Accelerant (BCA) by Manufacturer

3.1 Global Blood Clotting Accelerant (BCA) Sales Quantity by Manufacturer (2021-2026)
3.2 Global Blood Clotting Accelerant (BCA) Revenue by Manufacturer (2021-2026)
3.3 Global Blood Clotting Accelerant (BCA) Average Price by Manufacturer (2021-2026)
3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Blood Clotting Accelerant (BCA) by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Blood Clotting Accelerant (BCA) Manufacturer Market Share in 2025
- 3.4.3 Top 6 Blood Clotting Accelerant (BCA) Manufacturer Market Share in 2025
3.5 Blood Clotting Accelerant (BCA) Market: Overall Company Footprint Analysis
- 3.5.1 Blood Clotting Accelerant (BCA) Market: Region Footprint
- 3.5.2 Blood Clotting Accelerant (BCA) Market: Company Product Type Footprint
- 3.5.3 Blood Clotting Accelerant (BCA) Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

4.1 Global Blood Clotting Accelerant (BCA) Market Size by Region
- 4.1.1 Global Blood Clotting Accelerant (BCA) Sales Quantity by Region (2021-2032)
- 4.1.2 Global Blood Clotting Accelerant (BCA) Consumption Value by Region (2021-2032)
- 4.1.3 Global Blood Clotting Accelerant (BCA) Average Price by Region (2021-2032)
4.2 North America Blood Clotting Accelerant (BCA) Consumption Value (2021-2032)
4.3 Europe Blood Clotting Accelerant (BCA) Consumption Value (2021-2032)
4.4 Asia-Pacific Blood Clotting Accelerant (BCA) Consumption Value (2021-2032)
4.5 South America Blood Clotting Accelerant (BCA) Consumption Value (2021-2032)
4.6 Middle East & Africa Blood Clotting Accelerant (BCA) Consumption Value (2021-2032)

5 Market Segment by Type

5.1 Global Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
5.2 Global Blood Clotting Accelerant (BCA) Consumption Value by Type (2021-2032)
5.3 Global Blood Clotting Accelerant (BCA) Average Price by Type (2021-2032)

6 Market Segment by Application

6.1 Global Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
6.2 Global Blood Clotting Accelerant (BCA) Consumption Value by Application (2021-2032)
6.3 Global Blood Clotting Accelerant (BCA) Average Price by Application (2021-2032)

7 North America

7.1 North America Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
7.2 North America Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
7.3 North America Blood Clotting Accelerant (BCA) Market Size by Country
- 7.3.1 North America Blood Clotting Accelerant (BCA) Sales Quantity by Country (2021-2032)
- 7.3.2 North America Blood Clotting Accelerant (BCA) Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

8.1 Europe Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
8.2 Europe Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
8.3 Europe Blood Clotting Accelerant (BCA) Market Size by Country
- 8.3.1 Europe Blood Clotting Accelerant (BCA) Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Blood Clotting Accelerant (BCA) Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

9.1 Asia-Pacific Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
9.2 Asia-Pacific Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
9.3 Asia-Pacific Blood Clotting Accelerant (BCA) Market Size by Region
- 9.3.1 Asia-Pacific Blood Clotting Accelerant (BCA) Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Blood Clotting Accelerant (BCA) Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

10.1 South America Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
10.2 South America Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
10.3 South America Blood Clotting Accelerant (BCA) Market Size by Country
- 10.3.1 South America Blood Clotting Accelerant (BCA) Sales Quantity by Country (2021-2032)
- 10.3.2 South America Blood Clotting Accelerant (BCA) Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

11.1 Middle East & Africa Blood Clotting Accelerant (BCA) Sales Quantity by Type (2021-2032)
11.2 Middle East & Africa Blood Clotting Accelerant (BCA) Sales Quantity by Application (2021-2032)
11.3 Middle East & Africa Blood Clotting Accelerant (BCA) Market Size by Country
- 11.3.1 Middle East & Africa Blood Clotting Accelerant (BCA) Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Blood Clotting Accelerant (BCA) Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

12.1 Blood Clotting Accelerant (BCA) Market Drivers
12.2 Blood Clotting Accelerant (BCA) Market Restraints
12.3 Blood Clotting Accelerant (BCA) Trends Analysis
12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

13.1 Raw Material of Blood Clotting Accelerant (BCA) and Key Manufacturers
13.2 Manufacturing Costs Percentage of Blood Clotting Accelerant (BCA)
13.3 Blood Clotting Accelerant (BCA) Production Process
13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
14.2 Blood Clotting Accelerant (BCA) Typical Distributors
14.3 Blood Clotting Accelerant (BCA) Typical Customers

15 Research Findings and Conclusion

16 Appendix

16.1 Methodology
16.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Blood Clotting Accelerant (BCA) market size was valued at US$ 21.81 million in 2025 and is forecast to a readjusted size of US$ 32.80 million by 2032 with a CAGR of 6.1% during review period.
Blood Clotting Accelerant (BCA), also referred to as a clot activator, is a chemical substance used in laboratory medicine to dramatically speed up the natural coagulation (clotting) of blood samples. It is primarily coated on the interior walls of blood collection tubes to quickly yield serum for clinical testing.
In 2025, global production of Blood Clotting Accelerant (BCA) reached 196 tons, with an average selling price of USD 108 per kilogram and total production capacity of approximately 230 tons. The industry gross margin was around 30%–45%. Cost structure: direct materials accounted for about 62%, manufacturing overhead for about 30%, and labor costs for about 8%. Industry chain: upstream materials include medical-grade silica/silicon dioxide, thrombin or other clot-activating components, surfactants, dispersants, stabilizers, purified water, solvents, etc.; downstream customers are vacuum blood collection tube manufacturers.
The market for blood clotting accelerants is fundamentally tied to the rising volume of clinical diagnostic blood draws. Data from national health statistics agencies show continued growth in serum chemistry and immunoassay tests across outpatient, inpatient and health screening settings, directly sustaining consumption of coagulation activator tubes. Core performance requirements are rapid and complete clot formation with clean serum yield, free of interfering leachables, demanding strict control over clotting speed, compatibility with plastic tube walls and lot-to-lot consistency. According to technical bulletins on manufacturers’ websites and annual report disclosures, R&D efforts focus on purification of high-purity silica particles and enzymatic clotting agents to minimize analytical interference with trace element and therapeutic drug monitoring assays, while developing formulas that clot within minutes at room temperature to support emergency care and total lab automation workflows. On the regulatory side, EU IVDR and U.S. FDA oversight now extend to tube components, requiring BCA suppliers to provide comprehensive toxicological data and production quality records, giving a clear advantage to producers holding ISO 13485 certification and raw material traceability while steadily raising barriers for smaller uncertified players. In supply chain terms, Asia-Pacific manufacturing clusters for blood collection tubes drive substantial local BCA demand, whereas North America and Europe maintain strong appetite for advanced formulations combined with inert separator gels and for rapid-clot technologies suitable for low-volume pediatric draws. Competitive focus has shifted to high-purity, high-compatibility formulations and compliance-driven reliable delivery, with only those mastering refined processes and complete quality systems able to secure long-term partnerships with leading diagnostic consumable manufacturers.
This report is a detailed and comprehensive analysis for global Blood Clotting Accelerant (BCA) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Blood Clotting Accelerant (BCA) market size and forecasts, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
Global Blood Clotting Accelerant (BCA) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
Global Blood Clotting Accelerant (BCA) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Tons), and average selling prices (US$/Kg), 2021-2032
Global Blood Clotting Accelerant (BCA) market shares of main players, shipments in revenue ($ Million), sales quantity (Tons), and ASP (US$/Kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Blood Clotting Accelerant (BCA)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Blood Clotting Accelerant (BCA) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sekisui, Hubei New Desheng, Shanghai Tenghu Biological Technology, Improve Medical Technology, Guangzhou Jiean Bioscince & Technology, Wuhan Shangfei Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Blood Clotting Accelerant (BCA) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Liquid
Powder
Market segment by Tube Type
Clot Activator Tube
Gel & Clot Activator Tube
Market segment by Application
Biochemical Testing
Immunological Testing
Emergency Testing
Others
Major players covered
Sekisui
Hubei New Desheng
Shanghai Tenghu Biological Technology
Improve Medical Technology
Guangzhou Jiean Bioscince & Technology
Wuhan Shangfei Biotechnology
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Blood Clotting Accelerant (BCA) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Blood Clotting Accelerant (BCA), with price, sales quantity, revenue, and global market share of Blood Clotting Accelerant (BCA) from 2021 to 2026.
Chapter 3, the Blood Clotting Accelerant (BCA) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Blood Clotting Accelerant (BCA) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Blood Clotting Accelerant (BCA) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Blood Clotting Accelerant (BCA).
Chapter 14 and 15, to describe Blood Clotting Accelerant (BCA) sales channel, distributors, customers, research findings and conclusion.

Buy now